Irbesartan E Idroclorotiazide Aurobindo (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure.

• Hypertension: lowers systolic and diastolic pressure by blocking angiotensin II and increasing urinary sodium excretion.
• Diastolic hypertension: specifically reduces elevated diastolic values through combined vasodilation and diuresis.
• Hypertension with fluid retention: provides blood pressure control while reducing excess extracellular fluid.

• Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume, together resulting in reduced systemic vascular resistance and blood pressure.

Common Side Effects

• Dizziness: feeling light‑headed, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: particularly low potassium levels.
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe dehydration: marked fluid loss requiring medical attention.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: dangerously high potassium levels.
• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Blood dyscrasias: rare blood cell abnormalities.
• Severe hypotension: dangerously low blood pressure.

Before initiating therapy, consider the following safety measures.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Electrolyte assessment: regularly check potassium and sodium levels.
• Renal function evaluation: assess creatinine and eGFR, especially in patients with pre‑existing kidney disease.
• Caution in elderly: increased sensitivity to blood pressure changes and electrolyte disturbances.
• Avoid in severe hepatic impairment: limited data on safety.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan/HCTZ may interact with several medicines; review patient medication lists.

Major Interactions (Avoid)

• Aliskiren: combined use can increase risk of renal dysfunction.
• Potassium‑sparing diuretics or supplements: may cause hyperkalemia.
• Lithium: increased lithium levels and toxicity.
• ACE inhibitors or other ARBs: additive effects on blood pressure and renal function.
• NSAIDs: can reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may require dose adjustment to avoid hypotension.
• Antidiabetic agents: diuretic effect may alter glucose control.
• CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma levels.
• Thiazide‑type diuretics: additive electrolyte disturbances.
• Warfarin: potential alteration of INR, monitor coagulation status.